My HPRA: Register

GABAPENTIN ROSEMONT

50 Mg/Ml Oral Solution

Rosemont Pharmaceuticals LtdPA0312/025/001

SPC: DATE OF REVISION OF THE TEXT

14 Jul 2017 - 03 Oct 2017	03 Oct 2017 - Present
June2017	September 2017

« Back

Follow medicine

Print

Latest Changes to Medicine Info & SPC

03 Oct 2017
SPC: DATE OF REVISION OF THE TEXT
03 Oct 2017
SPC: Overdose
03 Oct 2017
SPC: Undesirable effects
03 Oct 2017
SPC: Special warnings and precautions for use
14 Jul 2017
SPC: DATE OF REVISION OF THE TEXT
14 Jul 2017
SPC: Preclinical safety data
14 Jul 2017
SPC: Pharmacokinetic properties
14 Jul 2017
SPC: Pharmacodynamic properties
14 Jul 2017
SPC: Overdose
14 Jul 2017
SPC: Undesirable effects
14 Jul 2017
SPC: Effects on ability to drive and use machines
14 Jul 2017
SPC: Fertility, pregnancy and lactation
14 Jul 2017
SPC: Interaction with other medicinal products and other forms of interaction
14 Jul 2017
SPC: Special warnings and precautions for use
14 Jul 2017
SPC: Contraindications
14 Jul 2017
SPC: Posology and method of administration
24 Mar 2017
SPC: DATE OF REVISION OF THE TEXT
24 Mar 2017
SPC: MARKETING AUTHORISATION HOLDER
24 Mar 2017
SPC: Special precautions for disposal
24 Mar 2017
SPC: Pharmacokinetic properties
24 Mar 2017
SPC: Undesirable effects
24 Mar 2017
SPC: Fertility, pregnancy and lactation
24 Mar 2017
SPC: Contraindications
24 Mar 2017
SPC: Posology and method of administration
28 Oct 2015
Marketing Status
14 Aug 2015
Marketing Status

Please note changes to the medicine information and summary of product characteristics are only available from the 19/05/2015 onwards. Changes made before this date aren't available online.

Important information regarding cookies and the HPRA

By using this website, you consent to the use of cookies in accordance with the HPRA Cookie Policy.
For more information on cookies, see our cookie policy.

Click here to accept the cookie policy and hide this message